![Foto de José](/img/nophoto.png)
José
López Aldeguer
Publicacións nas que colabora con José López Aldeguer (13)
2022
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
2020
-
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573
-
How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
HIV Medicine, Vol. 21, Núm. 2, pp. 128-134
2019
-
Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain
Open Forum Infectious Diseases, Vol. 6, Núm. 2
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202
-
HTLV testing of solid organ transplant donors
Clinical Transplantation
-
HTLV-1 infection in solid organ transplant donors and recipients in Spain
BMC Infectious Diseases, Vol. 19, Núm. 1
2018
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
-
Human T-lymphotropic virus type 1 infection and disease in Spain
AIDS, Vol. 31, Núm. 12, pp. 1653-1663
2014
-
HIV-2 and HTLV-1 infections in Spain, a non-endemic region
AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159
-
HIV-2 viral tropism influences CD4+ T cell count regardless of viral load
Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194
2013
-
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
AIDS, Vol. 27, Núm. 1, pp. 81-85
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092